ReviewJournal of diabetes investigation2020
Pancreatic stellate cells in the islets as a novel target to preserve the pancreatic β-cell mass and function.
Review in Journal of diabetes investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Integrative Spatial Omics for Systems-Level Mapping of Pathological Niches.bioRxiv : the preprint server for biology · 2025Article
- Response of Pancreatic Stellate Cells to the Development of Experimental Type 2 Diabetes Mellitus.Bulletin of experimental biology and medicine · 2025Article
- Scaffold-free endocrine tissue engineering: role of islet organization and implications in type 1 diabetes.BMC endocrine disorders · 2025Review
- Antagonizing IL-6 receptor restores pancreatic tissue resident NK cells activation and ameliorates pancreatic injury in the mouse model of MASH.Frontiers in pharmacology · 2025Article
- Vagal Splenic-Dependent Effects Influence Glucose Homeostasis, Insulin Secretion, and Histopathology of the Endocrine Pancreas in Hypothalamic Obese Male Rats: Vagus Nerve and Spleen Interactions Affect the Endocrine Pancreas.TheScientificWorldJournal · 2025Article
- Nanomedicine regulating PSC-mediated intercellular crosstalk: Mechanisms and therapeutic strategies.Acta pharmaceutica Sinica. B · 2024Review
- 1,25(OH)Endocrine · 2024Article
- Pancreatic stellate cells support human pancreatic β-cell viabilityMaterials today. Bio · 2024Article
- Pancreatic stellate cells: Key players in pancreatic health and diseases (Review).Molecular medicine reports · 2024Review
- Identification of a pancreatic stellate cell gene signature and lncRNA interactions associated with type 2 diabetes progression.Frontiers in endocrinology · 2024Article
- Integrated Physiology of the Exocrine and Endocrine Compartments in Pancreatic Diseases: Workshop Proceedings.Diabetes · 2023Review
- A single-cell human islet interactome atlas identifies disrupted autocrine and paracrine communications in type 2 diabetes.NAR genomics and bioinformatics · 2022Article
- The Impact of Pancreatic Exocrine Diseases on the β-Cell and Glucose Metabolism-A Review with Currently Available Evidence.Biomolecules · 2022Review
- Pancreatic stellate cells - rising stars in pancreatic pathologies.Physiological research · 2021Review
- Recapitulating pancreatic cell-cell interactions through bioengineering approaches: the momentous role of non-epithelial cells for diabetes cell therapy.Cellular and molecular life sciences : CMLS · 2021Review
- Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer.Biomolecules · 2021Review
- Glucotoxicity Activation of IL6 and IL11 and Subsequent Induction of Fibrosis May Be Involved in the Pathogenesis of Islet Dysfunction.Frontiers in molecular biosciences · 2021Article
- Review
- Pancreatic stellate cells in the islets as a novel target to preserve the pancreatic β-cell mass and function.Journal of diabetes investigation · 2020Review
- Dynamics of Cytokine Profile Indicators Changes in Animals with Acute Generalized Peritonitis on the Background of Diabetes Mellitus.Journal of medicine and lifeArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are numerous lines of clinical evidence that inhibition of the renin-angiotensin system (RAS) can prevent and delay the development of diabetes. Also, the role of RAS in the pathogenesis of diabetes, including insulin resistance and β-cell dysfunction, has been extensively investigated. Nevertheless, this role had not yet been fully shown. A variety of possible protective mechanisms for RAS blockers in the regulation of glucose homeostasis have been suggested. However, the direct effect on pancreatic islet fibrosis has only recently been spotlighted. Various degrees of islet fibrosis are often observed in the islets of patients with type 2 diabetes mellitus, which can be associated with a decrease in β-cell mass and function in these patients. Pancreatic stellate cells are thought to be deeply involved in this islet fibrosis. In this process, the activation of RAS in islets is shown to transform quiescent pancreatic stellate cells into the activated form, stimulates their proliferation and consequently leads to islet fibrotic destruction. In this article, we introduce existing clinical and experimental evidence for diabetes prevention through inhibition of RAS, and review the responsible local RAS signaling pathways in pancreatic stellate cells. Finally, we propose possible targets for the prevention of islet fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.